To confirm whether DPP4 inhibitor, anagliptin, could potentiate the anti-tumor effect of PD-L1 blockade therapy, a syngeneic animal model was established in C57BL/6 mice by subcutaneous injection of murine Lewis lung cancer. Here, DPP4 is linked to neoplasm.